ERBB2 and breast carcinoma: JBCRG-08 was a randomized, multicenter, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence, and their combination in patients with HER2/ErbB2-positive primary breast cancer (BIG 2-06/N063D/EGF 106708).